ERA1 Inhibitors
Chemical inhibitors of ERA1 can exert their effects through various modes of action, each targeting different aspects of the kinase signaling pathways to which ERA1 is integral. Staurosporine stands out as a broad-spectrum kinase inhibitor, directly impeding the kinase activity of ERA1 by obstructing the ATP binding site, which is crucial for its phosphorylation activity. Bisindolylmaleimide I approaches the inhibition of ERA1 indirectly by selectively inhibiting protein kinase C (PKC), a kinase that operates within the same signaling pathways as ERA1. By curtailing PKC activity, Bisindolylmaleimide I reduces the phosphorylation cascade that ERA1 might typically propagate.
Moreover, H-89 can curtail ERA1's functionality by targeting protein kinase A (PKA), which phosphorylates substrates that could interact with ERA1 or lie upstream of it, thereby indirectly mitigating ERA1's role in signal transduction. Similarly, LY294002 and Wortmannin disrupt the PI3K/AKT signaling pathway, of which ERA1 may be a part, by inhibiting PI3K and consequently diminishing the activity of downstream components associated with ERA1. PD98059 and U0126, both MEK inhibitors, impede the MAPK/ERK pathway, upstream of ERA1, thereby inhibiting the activation and function of ERA1 within this particular signaling route. Inhibitors like SB203580 and SP600125, which target p38 MAPK and JNK respectively, also serve to dampen the signaling pathways that involve ERA1, with SB203580 focusing on stress response pathways and SP600125 on JNK-mediated pathways. Lastly, Rapamycin inhibits mTOR, a key component of the PI3K/AKT/mTOR pathway, to which ERA1 might contribute, resulting in a decrease in ERA1 activity, while PP2 impedes Src family kinases that could phosphorylate ERA1 or its associated components. Gefitinib, by inhibiting EGFR tyrosine kinase, can also reduce the signaling activity leading to ERA1's involvement in various cellular processes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor that targets a wide range of kinases. It can inhibit ERA1 by blocking its kinase activity, which is essential for its function in signal transduction processes. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I selectively inhibits protein kinase C (PKC), which is involved in the same signaling pathways as ERA1. Inhibition of PKC can reduce the phosphorylation events that ERA1 may propagate, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can disrupt PI3K/AKT signaling, a pathway in which ERA1 may be involved. By inhibiting this pathway, LY294002 can reduce the activity of downstream effectors, including ERA1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream of the MAPK/ERK pathway, a known associate of ERA1 signaling. By inhibiting MEK, PD98059 can suppress the activation of the MAPK/ERK pathway, thereby inhibiting ERA1's functional contribution to this signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that can prevent the activation of the MAPK/ERK pathway. Like PD98059, it can indirectly inhibit ERA1 by blocking the signaling events that lead to ERA1's activation and function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If ERA1 is associated with the p38 MAPK pathway, inhibition of p38 MAPK can lead to reduced ERA1 signaling, as p38 MAPK is involved in stress response signaling pathways where ERA1 may play a role. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can be involved in signaling pathways associated with ERA1. Inhibition of JNK can impair the signaling mechanisms in which ERA1 might be involved, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. By inhibiting PI3K, it disrupts the PI3K/AKT pathway, which can be essential for ERA1's role in signal transduction, leading to a decrease in ERA1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the PI3K/AKT/mTOR pathway. Given ERA1's potential involvement in this pathway, inhibition of mTOR by rapamycin can result in the functional inhibition of ERA1. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. Since Src kinases can phosphorylate and activate multiple targets in various signaling pathways, including those associated with ERA1, inhibition by PP2 can lead to a decrease in ERA1 activity. | ||||||